ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "anti-TNF therapy"

  • Abstract Number: 1276 • 2015 ACR/ARHP Annual Meeting

    Improvement in Work and Household Productivity for Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with Anti-TNFs in Routine Clinical Practice in Turkey

    Sebnem Ataman1, Mehmet Kirnap2, Buminhan Seferoglu3, Zuhal Altay4, Aylin Rezvani5, Omer Kuru6,7, Erhan Capkin8, Nazli Derya Bugdayci9, Ilhan Sezer10, Hasan Fatih CAY11 and Akinci Tan12, 1Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey, 2Department of Physical Medicine and Rehabilitation, Erciyes University, Kayseri, Turkey, 3Physical Medicine and Rehabilitation, Ataturk University Medical School, Erzurum, Turkey, 4ELAZIG KARAYOLU UZERI, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey, 5Department of Physical Medicine and Rehabilitation, Bezmialem Foundation University, İstanbul, Turkey, 6Kurupelit Mevkii Kurupelit 552, Ondokuz Mayis Univ.Tip Fak.Has.-Fizik Tedavi, Samsun, Turkey, 7Physical Medicine and Rehabilitation, Ondokuz Mayis University, Samsun, Turkey, 8PM&R AND RHEUMATOLOGY, Karadeniz Tecnical University, Faculty of Medicine, TRABZON, Turkey, 9Physical Treatment and Rehabilitation, Istanbul Physical Treatment and Rehabilitation Training and Research Hospital, Istanbul, Turkey, 10Rheumatology, Physical Medicine and Rheabilitation, Antalya Education and Research Hospital, Antalya, Turkey, 11Rheumatology, Physical Medicine&Rehabilitation, Antalya Education and Research Hospital, Antalya, Turkey, 12Physical Med & Rehab, Hacettepe Univ, Ankara, Turkey

    Background/Purpose: The impact of  rheumatoid arthritis (RA) and ankylosing spondylitis (AS)  on paid work is measured on the basis of employed people missing time from…
  • Abstract Number: 2060 • 2015 ACR/ARHP Annual Meeting

    Microscopic Bowel Inflammation in Spondyloarthritis As a Baseline Predictor of Anti-TNF Response

    Heleen Cypers, Gaëlle Varkas, Filip van Den Bosch and Dirk Elewaut, Rheumatology, Ghent University Hospital, VIB, Ghent, Belgium

    ·      Background/Purpose: Microscopic bowel inflammation without associated gastro-intestinal symptoms is present in up to 50% of spondyloarthritis (SpA) patients. Two types of inflammation are distinguished based…
  • Abstract Number: 2860 • 2015 ACR/ARHP Annual Meeting

    Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol

    Arthur Kavanaugh1, Dafna Gladman2, Désirée van der Heijde3, Oana Purcaru4 and Philip J. Mease5, 1University of California San Diego, La Jolla, CA, 2University of Toronto, Toronto, ON, Canada, 3Leiden University Medical Center, Leiden, Netherlands, 4UCB Pharma, Brussels, Belgium, 5Rheumatology Research, Swedish Medical Center, Seattle, WA

    Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…
  • Abstract Number: 599 • 2015 ACR/ARHP Annual Meeting

    An Examination of Dose Escalation Among Remicade (infliximab) Users in a US RA Registry

    Jeffrey R. Curtis1, Ying Shan2, Joel M. Kremer3, Katherine Saunders4, Dennis Parenti5 and Shelly Kafka5, 1University of Alabama at Birmingham, Birmingham, AL, 2UMass Memorial Medical Center, Worcester, MA, 3Albany Medical College, Albany, NY, 4Corrona LLC, Atlanta, GA, 5Janssen Scientific Affairs, LLC, Horsham, PA

    Background/Purpose: Limited data are available about infliximab(IFX) dose escalation. This analysis examines the frequency of dose escalation among IFX patients using data from the US…
  • Abstract Number: 1313 • 2015 ACR/ARHP Annual Meeting

    Tumour Necrosis Factor Inhibitor Treatment Normalises Hand Bone Loss in a Minority of Rheumatoid Arthritis Patients Treated in Clinical Practice. Results from the Copenhagen Osteoarthritis Study and the Danbio Registry

    Lykke Midtbøll Ørnbjerg1, Mikkel Østergaard1, Trine David Jensen2, Pernille Bach Mortensen2, Lars Hyldstrup2, Pernille Boyesen3, Anja Thormann1, Ulrik Tarp1, Wolfgang Bøhme1, Hanne Lindegaard1, Uta Engling Poulsen1, Annette Hansen1, Annette Schlemmer1, Niels Graudal1, Anne Rødgaard Andersen1, Jakob Espesen1, Gina Kollerup1, Bente Glintborg1, Ole Rintek Madsen1, Dorte Vendelbo Jensen1 and Merete Lund Hetland1, 1DANBIO, On behalf of Depts of Rheumatology, North, South, Central, Zealand and Capital Region, Copenhagen, Denmark, 2Dept. of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark, 3Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Rheumatoid arthritis (RA) is characterised by progressive joint destruction and loss of periarticular bone mass. Thus hand bone loss (HBL) has been proposed as…
  • Abstract Number: 2105 • 2015 ACR/ARHP Annual Meeting

    Drug Survival and Cost Effectiveness in Patients on Reduced Dose Anti-TNF: Results of a 4 Year Prospective Observational Study

    John Stack1, Claire-Louise Murphy2, Clara Bannon1, Eithne Murphy1, Trevor Duffy1 and Maurice Barry1, 1Rheumatology, Connolly Hospital Blanchardstown, Dublin, Ireland, 2Rheumatology, Connolly Hospital Blanchardstow, Dublin, Ireland

    Background/Purpose: Anti-TNF-α drugs are effective treatments for patients with inflammatory arthritis (IA). They are however expensive and their use carries a significant cost burden to…
  • Abstract Number: 2862 • 2015 ACR/ARHP Annual Meeting

    Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review

    Victoria Navarro-Compán1, Chamaida Plasencia-Rodriguez2, Eugenio De Miguel1, Alejandro Balsa1, Emilio Martín-Mola1, Daniel Seoane-Mato3 and Juan D. Cañete4, 1Rheumatology, University Hospital La Paz, Madrid, Spain, 2Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, 3Research Unit, Spanish Society of Rheumatology, Madrid, Spain, 4Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain

    Background/Purpose: Anti-TNF therapy is successful for achieving low disease activity (LDA) or clinical remission in patients with axial spondyloarhritis (axSpA). Nevertheless, this therapy has not…
  • Abstract Number: 2558 • 2014 ACR/ARHP Annual Meeting

    Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures

    M.a.C. van der Weijden1,2, J.C. van Denderen2, W.F. Lems1, M.T. Nurmohamed1,2, B.a.C Dijkmans1,2 and I.E. van der Horst-Bruinsma1, 1Rheumatology, VU University Medical Center, Amsterdam, Netherlands, 2Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands

    Background/Purpose Ankylosing spondylitis (AS) is characterized by chronic inflammation often leading to ankylosis of the spine, but also by a decrease of bone mineral density…
  • Abstract Number: 1603 • 2014 ACR/ARHP Annual Meeting

    Effect of Methotrexate on the Immunogenicity of TNF Inhibitors in Spondyloarthritis Patients

    Alejandro Villalba1, Chamaida Plasencia-Rodriguez1, Diana Peiteado1, Laura Nuño2, Gema Bonilla3, Alejandro Balsa4, Emilio Martín-Mola5 and Dora Pascual-Salcedo6, 1Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, 2Hospital La Paz-IdiPaz, Madrid, Spain, 3Rheumatology, Hospital La Paz, Madrid, Spain, 4Reumatology, Hospital Universitario La Paz, Madrid, Spain, 5Rheumatology, Hospital Universitario La Paz, Madrid, Spain, 6Immunology, La Paz University Hospital, Madrid, Spain

    Background/Purpose: The spondyloarthritis (SpA) patients treated under TNF inhibitors (TNFi)  with detectable antidrug antibodies (ADA) often develop  loss of efficacy. Concomitant therapy with  methotrexate (MTX)…
  • Abstract Number: 573 • 2014 ACR/ARHP Annual Meeting

    Three-Year Course and Prediction of Physical Functioning in Ankylosing Spondylitis Patients Treated with TNF-Inhibitors

    Salima F.E. van Weely1, Eva L. Kneepkens1, Mike T. Nurmohamed1, Joost Dekker1,2 and Irene E. van der Horst-Bruinsma3, 1Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, 2Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, 3Rheumatology, VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: Currently, only limited information is available on the long-term course of limitations in physical functioning and spinal mobility in Ankylosing Spondylitis (AS) patients receiving…
  • Abstract Number: 272 • 2014 ACR/ARHP Annual Meeting

    Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers

    Rebecca Davies1, Lianne Kearsley-Fleet1, Eileen Baildam2, Michael W. Beresford3, Helen E. Foster4, Taunton R. Southwood5, Wendy Thomson6, Kimme L. Hyrich7, on Behalf Of The BSPAR Etanercept Cohort Study1 and The Biologics for Children with Rheumatic Diseases (BCRD) study1, 1Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, 3Alder Hey Children's NHS Foundation Trust Hospital, Institute of Translational Medicine (Child Health), University of Liverpool, Liverpool, United Kingdom, 4Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, 5Institute of Child Health, University of Birmingham and Birmingham Children's Hospital, Birmingham, United Kingdom, 6Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 7Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom

    Background/Purpose: The management of juvenile idiopathic arthritis (JIA) has been revolutionised by the introduction of biologics such as etanercept (ETN), approved in the UK in…
  • Abstract Number: 2565 • 2014 ACR/ARHP Annual Meeting

    The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis

    Michael J. Nissen1, Adrian Ciurea2, Juerg Bernhard3, Rudiger Muller4, Giorgio Tamborrini5, Martin Toniolo6, Cem Gabay7 and Axel Finckh1, 1Rheumatology, Geneva University Hospital, Geneva, Switzerland, 2Gloriastrasse 25, Rheumaklinik, Universitatsspital Zurich, Zurich, Switzerland, 3Rheumatology, Solothurn Hospital, Solothurn, Switzerland, 4Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, 5Department of Rheumatology and Musculoskeletal Ultrasound, Bethesda Hospital Basel, Basel, Switzerland, 6Department of Rheumatology, University Hospital of Zurich, Zurich, Switzerland, 7University Hospitals of Geneva/SCQM Registry, Geneva, Switzerland, Geneva, Switzerland

    Background/Purpose: Randomized clinical trials and current recommendations suggest little role for disease-modifying anti-rheumatic drugs (DMARDs) as co-therapy with anti-TNF (aTNF) agents in patients with axial-spondyloarthritis…
  • Abstract Number: 1596 • 2014 ACR/ARHP Annual Meeting

    Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondylarthritidies (SpA)

    Saedis Saevarsdottir1, Michele Santacatterina2, Carl Turesson3, Helena Forsblad4, Lennart Jacobsson4 and Staffan Lindblad5, 1Rheumatology Unit, Department of Medicine, Karolinska institutet and Karolinska University Hospital, Stockholm, Sweden, 2Biostatistics Core Facility, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, 3Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 4Dept of Rheumatology & Inflammation Research, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, 5Department of Learning, Informatics, Management and Ethics, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose Golimumab is a TNF inhibiting biological drug that was approved in Sweden in 2010 for the treatment of RA, PsA and AS. Our previous…
  • Abstract Number: 572 • 2014 ACR/ARHP Annual Meeting

    Objective Evaluation of Physical Functioning after TNFi Therapy in Ankylosing Spondylitis Patients; A Selection of Three Feasible Performance-Based Tests

    Salima F.E. van Weely1, Joost Dekker1,2, Martijn P.M. Steultjens3, Christiaan J. Van Denderen1, Mike T. Nurmohamed1, Ben A.C. Dijkmans4 and Irene E. van der Horst-Bruinsma4, 1Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands, 2Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, 3Institute for Applied Health Research and School of Health and Life Sciences, Glasgow Caledonian University, Glasgow, Scotland, 4Rheumatology, VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: Physical functioning is considered an important outcome domain for the evaluation of the effectiveness of therapy and the course of the disease. In an effort…
  • Abstract Number: 248 • 2014 ACR/ARHP Annual Meeting

    Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF?

    Proton Rahman1, Algis Jovaisas2, William Bensen3, Wojciech Olszynski4, Anna Jaroszynska5, Philip Baer6, Maqbool Sheriff7, Dalton Sholter8, Eliofotisti Psaradellis9, John S. Sampalis9, Francois Nantel10, Allen J Lehman11, Susan Otawa11 and May Shawi10, 1Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 2194 Main Street, University of Ottawa, Ottawa, ON, Canada, 3Division of Rheumatology, McMaster University, Hamilton, ON, Canada, 4University of Saskatchewan, Saskatoon, SK, Canada, 5Private Practice, Burlington, ON, Canada, 6Private Practice, Scarborough, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8University of Alberta, Edmonton, AB, Canada, 9JSS Medical Research, Montreal, QC, Canada, 10Janssen Inc., Toronto, ON, Canada, 11Medical Affairs, Janssen Inc., Toronto, ON, Canada

    Background/Purpose The present standard for measuring disease activity in AS is the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) which focuses on five major symptoms…
  • « Previous Page
  • 1
  • …
  • 15
  • 16
  • 17
  • 18
  • 19
  • …
  • 29
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology